DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20161658

Single dose methotrexate for the treatment of unruptured ectopic pregnancy: experience in Kemaman Hospital, Terengganu, Malaysia

Azny Syahirah Mohamad Yusof, Zahar Azuar Zakaria

Abstract


Background: The objective of this study was to review our experience with single dose intramuscular methotrexate (MTX) for the treatment of ectopic pregnancy and to evaluate the safety and efficacy of the treatment modality.

Methods: A prospective study was carried out at Kemaman Hospital, Terengganu, Malaysia. A database was started and continued prospectively for patients meeting all the criteria’s for MTX therapy from January 2015 till January 2016. The selection criteria’s were patients who were asymptomatic or experience mild symptoms but haemodynamically stable and ectopic gestational mass of less than 4cm on ultrasound. Intramuscular methotrexate (MTX) 50mg/m2 was administered as in-patient and monitored at least 24 hours for side effects. Upon discharge, blood samples were collected on day 4 and day 7 of MTX therapy and weekly to 2-weekly thereafter until hCG titers became < 2mIU/mL.

Results: 4 patients opted for medical treatment. All patients received only a single dose methotrexate and did not have complications post medical treatment. hCG level reached normalization within 30 days and 1 patient had longer follow up until 120 days. Higher patient satisfaction in all patients due to the noninvasive nature of the treatment modality.

Conclusions: This study showed that medical treatment of ectopic pregnancy with systemic single dose methotrexate can be a primary treatment modality for selected patients with stable unruptured tubal pregnancy.


Keywords


Methotrexate, Ectopic pregnancy

Full Text:

PDF

References


Walker JJ. Ectopic pregnancy. Clinical Obstetrics and Gynaecology. 2007;50(1):89-99.

Della-Guistina D, Denny M. Ectopic Pregnancy. Emergency Medicine Clinics of North America. 2003;21(3):565-84.

Varma R, Gupta J. Tubal ectopic pregnancy. Clinical Evidence. 2009:1406.

Sivalingam V, Duncan W, Kirk E, Shephard L. Diagnosis and management of ectopic pregnancy. Journal of Family Planning and Reproductive Health Care. 2011;37:231-40.

Rodi IA, Sauer MV, Gorril MJ. The medical treatment of unruptured ectopic pregnancy with methotrexate and citrovorum rescue:preliminary experience. Fertility and Sterility. 1986;46(5):811-3.

Stovall TG, Ling FW, Buster JE. Outpatient chemotherapy of unruptured ectopic pregnancy. Fertility and Sterility. 1989;51(3):435-8.

Stovall TG, Ling FW. Single dose methotrexate: an expanded clinical trial. The American Journal of Obstetrics and Gynaecology. 1993;168(6):1759-65.

Hajenius PJ, Engelsbel S, Mol BWJ. Randomised trial of systemic methotrexate versus laparoscopic salpingostomy in tubal pregnancy. The Lancet. 1997;350(9080):774-9.

Morlock RJ, Lafata JE, Eisenstein D. Cost-effectiveness of single dose methotrexate compared with laparoscopic treatment of ectopic pregnancy. Obstetrics and Gynaecology. 2000;95(3):407-12.

Sendy F, Alshehri E, Alajmi A. Failure rate of single dose methotrexate in management of ectpic pregnancy. Obstetrics and Gynaecology International. 2015 Article ID 902426, 5 pages.

Potter MB, Lepine LA, Jamieson DJ. Predictors of success with methotrexate treatment of tubal ectopic pregnancy at Grady Memorial Hospital. The American Journal of Obstetrics and Gynaecology. 2003;188(5):1192-4.